This study analyzes how leading pharmaceutical companies are strategically leveraging the medical liaison function. As a subscriber to this study, you will learn how to best maximize the use of this type of personnel. For each target company, the study provides the following information:

• Strategic approach to the medical liaison function
• Response to OIG guidelines
• Organizational structure/reporting relationships by title
• Distribution of personnel by business unit/therapeutic area
• Key roles by title
• Typical salary range by title
• Description of incentive package by title
• Evaluation methods

The study also analyzes each company's philosophy about the medical liaison function, including:

• Quantitative and qualitative methods for valuing the function
• Implications of Office of Inspector General guidelines and recent litigation on the liaison role

For companies interested in this type of information on a global scale, a similar program is offered that covers companies in the five major countries in Europe.